期刊文献+

低钠血症398例临床特征分析 被引量:6

Retrospective cohort study of hyponatremia in hospitalized patients
下载PDF
导出
摘要 目的分析低钠血症的病因、转归及特点,为本地低钠血症的临床流行病学研究提供初步资料。方法收集2012年6月—2013年12月于大连医科大学附属第一医院住院的低钠血症患者临床资料,按照血清钠离子(Na+)浓度分为轻度低钠血症组(130≤Na+<135 mmol/L),中度低钠血症组(120≤Na+<130 mmol/L)以及重度低钠血症组(Na+<120 mmol/L),分析病因、各组转归、合并症情况及血钠水平的影响因素等。结果 398例低钠血症在住院患者中的发病率0.03%,根据基础疾病进行分析,其中以肺部疾病103例(占25.88%),中枢神经系统疾病74例(占18.59%),恶性肿瘤56例(占14.07%),消化系统疾病53例(占13.32%)居多。重度组死亡率高于轻、中度组(P<0.05)。年龄、肾小球滤过率与血Na+呈负相关;血Cl-、血渗透压与血Na+呈正相关,差异有显著性意义(P<0.05)。结论低钠血症是住院患者常见的并发症,主要原因是肺部疾病、中枢神经系统疾病、恶性肿瘤;随着年龄增长、肾小球滤过率升高时容易合并低钠血症。早期识别、正确处理能降低低钠血症的发生率和病死率。 Objective To retrospectively analyze the causes,outcomes and characteristics of hyponatremia and to provide preliminary reference for clinical epidemiological study of hyponatremia in the local area. Methods Clinical data of inpatients with hyponatremia were collected. Etiologies and outcomes of hyponatremia were summarized. Results The incidence of hyponatremia was 0. 03% in the 398 inpatients,who were hospitalized by lung diseases( 25. 88%),central nervous system diseases( 18. 59%) or malignant tumor( 14. 07%). The mortality rate in the severe hyponatremia group was higher than the mild and moderate groups. Age and glomerular filtration rate were negatively correlated with blood sodium level;whereas blood chloride and osmotic pressure were positively correlated. Conclusion Hyponatremia is a common complication in hospitalized patients with lung diseases,central nervous system diseases or malignant tumor. Patients with older age and higher glomerular filtration rate are more vulnerable for hyponatremia. Early recognition and appropriate treatment can reduce the morbidity and mortality of hyponatremia.
出处 《大连医科大学学报》 CAS 2014年第5期460-463,474,共5页 Journal of Dalian Medical University
关键词 低钠血症 分类 病因 hyponatremia classification pathogeny
  • 相关文献

参考文献18

  • 1Whelan B,Bennett K,0Giordan D,et al. Serum sodium asa risk factor for inhospital mortality in acute unselected gen-eral medical patients[ J]. QJM ,2009,102( 3 ) : 175 - 182.
  • 2陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社.2008:251.
  • 3Karin Olsson,Bertil Ohlin,Olle Melander. Epidemiologyand characteristics of hyponatremia in the emergency de-partment [J]. Eur J Intern Med, 2013 , 24(2): 110 -116.
  • 4Hawkins RC. Age and gender as risk factors for hyponatre-mia and hypernatremia [ J ]. Clin Chim Acta, 2003 , 337(12): 169 -172.
  • 5Sajadieh A,Binici Z,Mouridsen MR,et al. Mild hyponatre-mia carries a poor prognosis in community subjects[ J] . AmJ Med,2009,122(7) : 679 -686.
  • 6Waikar SS,Mount DB,Curhan GC. Mortality after hospitali-zation with mild,moderate, and severe hyponatremia [ J ].Am J Med,2009,122(9) : 857 -865.
  • 7Wald R, Jaber BL, Price LL,et al. Impact of hospital - as-sociated hyponatremia on selected outcomes [ J ]. Arch In-tern Med, 2010, 170(3) : 294 -302.
  • 8Gill G, Huda B, Boyd A, et al. Characteristics and mor-tality of severe hyponatremia hospital - based study [ J ].Clin Endocrinol, 2006, 65(2) : 246 -249.
  • 9Saeed BO, Beaumont D, Handley GH, et al. Severe hy-ponatremia :investigation and management in a district gen-eral hospital[ J ]. J Clin Pathol, 2002, 55 ( 12): 893 -896.
  • 10Swart RM, Hoorn EJ, Betjes MG, et al. Hyponatremiaand inflammation : the emerging role of interleukin - 6 inosmoregulation [ J ]. Nephron Physiol,2011,118 ( 2 ):45-51.

二级参考文献45

  • 1陈艺坛,陈志斌.低钠血症对老年人心力衰竭预后的影响[J].临床军医杂志,2004,32(5):4-5. 被引量:7
  • 2卢江宁.肺心病急性加重期并发低钠血症49例分析[J].临床肺科杂志,2005,10(2):185-186. 被引量:8
  • 3Johnson C D, Perea-Lopez R M. Rodriguezl, acute, spinal, cord and head injury: case report and discusdsion of cardiac,respiratory and endocr/aeabnor realities [J]. Bol Asoc Med PR, 1998,90 (4-6) : 95 - 101.
  • 4Diring M N. Superceller and intrarentricular blood predict elevated plasma atrial natriurtic factor in SAH [J]. Stroke,1991,22(2):577-578.
  • 5Krenz N R, Weaver L C. Changes in the morphoiogy of sympathetic preganglionic neurons parallel the development of autowom is dysrefuxia after spind cord injury in riats[J]. Neurosci Lett,1998,243 (1-3) : 61-64.
  • 6Goenraad M J, Meinders A E, Taal J G, et al. Hypon-atermia in intracranial disorders [J]. Neth J Med,2001,58(3):123-127.
  • 7Abraham A, Jacob C K. Severe hyponatre mia:current concepts on pathogenesis and treatment[J]. Natt Med J India,2001,14(5):277-283.
  • 8Borron G, Maggi A, Sangiovanni A, et al. Clinical relevance of hyponatre mia for the hospital outcome of cirrhotic patients [J]. Dig Liver Dis,2000,32(7):605-610.
  • 9Levine JP, Stelnicki E, Weiner HL. Hyponatremia in the postoperative craniofacial pediatric patient population: a connection to cerebral salt wasting syndrome and management of the disorder. Plast Reconstr Surg, 2001,108:1501.
  • 10Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSWS. Trends Endocrinol Metab, 2003,14:182.

共引文献1858

同被引文献51

  • 1王玉祥,崔勇.老年人急性脑卒中引起脑心综合征416例分析[J].蚌埠医学院学报,2005,30(2):143-144. 被引量:15
  • 2Maybauer M O, Maybauer D M, Enkhbaatar P, et al. Physiology of the vasopressin receptors[J]. Best Pract Res Clin Anaesthesiol, 2008,22(2) ,253-263.
  • 3Proeino G, Barbieri C, Carmosino M, et al. Fluvastatin modulates re- nal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells[J]. Pflugers Arch,2011,462(5) : 753- 766.
  • 4Cheng C Y, Chu J Y, Chow B K. Vasopressimindependent mecha- nisms in controlling water homeostasis[J]. J Mol Endocrinol,2009, 43(3)~81-92.
  • 5Plosker G L. Tolvaptan[J]. Drugs, 2010,70 (4) :443 - 454.
  • 6Shoal S E,Bramer S L,Bricmont P,et al. Pharmacokinetic and pharma- codynamic interaction between tolvaptan,a non-peptide AVP antagonist, and furosemide orhydrochlomthiazide[J]. J Cardiovasc Pharmacol, 2007, 50(2) :213-222.
  • 7Rockville. Otsuka America Pharmaceutical [ M1. USA: Princeton, NJ,2009:1.
  • 8Shoal S, Ohzone Y, Ninomiya S. In vitro P-glycoprotein interaction and steady-state pharmaeokinetic interactions between tolvaptan and digoxin in healthy subjects[ J ]. J Clin Pharmacol, 2011,51 (5) 761 - 769.
  • 9Shoal S,Mallikaarjun S. Pharmacokinetic and pharmacodynamic in- teraction between tolvaptan and warfarin in healthy subjects[J]. Clin Pharmaeol Drug,2012,1(2) :67-75.
  • 10Kim S, Hasunuma T, Sato O. Pharmacokinetic, pharmacodynamic and safety of tolvaptan-A novel, oral, selective non-peptide AVP V2-reeeptor antagonist: Results of single-and multiple-dose studies in healthy Japanese male volunteers[J]. Cardlovasc Drugs Ther, 2011,25(Suppl 1) :5-17.

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部